ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Estrogen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0117

Its studies are mostly in Breast Neoplasms, led by Johnson & Johnson.

Furthest: phase 1, since Apr 6, 20261 company-led study, 1 open or runningNext primary completion: Apr 30, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson11 open or runningphase 1since Apr 6, 2026Apr 6, 2026Apr 30, 2028phase 1 · NCT07524855
  • Named in Johnson & Johnson’s own pipeline as JNJ-4362 (HLD-0117), phase 1, as of Oct 13, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 6, 2026First study: phase 1 study in Breast NeoplasmsFirst studyNCT07524855 · 170 planned · United States, Australia

Ahead

  1. Apr 30, 2028Primary completion: phase 1 study in Breast NeoplasmsNCT07524855

TargetBeta

“An orally bioavailable bifunctional small molecule composed of an estrogen receptor (ER)-binding moiety that is conjugated, via a linker, to a moiety that binds to an as of yet undisclosed pan-essential protein, with potential antineoplastic activity. Upon oral administration of ER-targeting regu…”NCIt, read by Claude

Other programs on ESR1

ProgramCompanyFurthest phaseStudies
Ethinyl EstradiolruleJohnson & Johnsonphase 470
EstradiolruleNovo Nordiskphase 469
FulvestrantruleAstraZenecaphase 430
TamoxifenruleAstraZenecaphase 421
ClomipheneruleHamad Medicalphase 43
vepdegestrantrulePfizerphase 320
camizestrantruleAstraZenecaphase 318
giredestrantHoffmann-La Rochephase 317
HRS-8080Jiangsu HengRui Medicinephase 313
elacestrantruleMenarini Groupphase 312
ImlunestrantruleEli Lillyphase 312
taragarestrantruleInventisBiophase 35

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07524855Breast Neoplasms · United States, Australia1RecruitingApr 30, 2028170

How it is read

Names in the registry

  • “JNJ-101684362 (HLD-0117)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.